869 related articles for article (PubMed ID: 18088159)
1. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness of neovascular age-related macular degeneration in Canada.
Cruess A; Zlateva G; Xu X; Rochon S
Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
[TBL] [Abstract][Full Text] [Related]
3. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].
Pauleikhoff D; Scheider A; Wiedmann P; Gelisken F; Scholl HP; Roider I; Mohr A; Zlateva G; Xu X
Ophthalmologe; 2009 Mar; 106(3):242-51. PubMed ID: 18709375
[TBL] [Abstract][Full Text] [Related]
4. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.
Soubrane G; Cruess A; Lotery A; Pauleikhoff D; Monès J; Xu X; Zlateva G; Buggage R; Conlon J; Goss TF
Arch Ophthalmol; 2007 Sep; 125(9):1249-54. PubMed ID: 17846366
[TBL] [Abstract][Full Text] [Related]
5. [Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].
Soubrane G; Zlateva G; Xu X; Buggage R; Kosa M
J Fr Ophtalmol; 2008 Feb; 31(2):138-45. PubMed ID: 18401314
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness of bilateral neovascular age-related macular degeneration in Spain.
Ruiz-Moreno JM; Coco RM; García-Arumí J; Xu X; Zlateva G
Curr Med Res Opin; 2008 Jul; 24(7):2103-11. PubMed ID: 18547463
[TBL] [Abstract][Full Text] [Related]
7. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.
Lotery A; Xu X; Zlatava G; Loftus J
Br J Ophthalmol; 2007 Oct; 91(10):1303-7. PubMed ID: 17504847
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
[TBL] [Abstract][Full Text] [Related]
9. Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():109-17. PubMed ID: 27038626
[TBL] [Abstract][Full Text] [Related]
10. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
Iskrov G; Astigarraga I; Stefanov R; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Schieppati A; Taruscio D; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():67-78. PubMed ID: 27042831
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
[TBL] [Abstract][Full Text] [Related]
12. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.
López-Bastida J; Linertová R; Oliva-Moreno J; Posada-de-la-Paz M; Serrano-Aguilar P; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Baji P; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():99-108. PubMed ID: 27038627
[TBL] [Abstract][Full Text] [Related]
13. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
Bandello F; Augustin A; Sahel JA; Benhaddi H; Negrini C; Hieke K; Berdeaux GH;
Drugs Aging; 2008; 25(3):255-68. PubMed ID: 18331076
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
Chuvarayan Y; Finger RP; Köberlein-Neu J
Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
[TBL] [Abstract][Full Text] [Related]
16. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
17. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study.
Angelis A; Mellerio JE; Kanavos P
Orphanet J Rare Dis; 2022 Sep; 17(1):346. PubMed ID: 36068590
[TBL] [Abstract][Full Text] [Related]
18. SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.
Brown MM; Brown GC; Lieske HB; Tran I; Turpcu A; Colman S
Retina; 2016 Feb; 36(2):285-98. PubMed ID: 26428606
[TBL] [Abstract][Full Text] [Related]
19. The impact of advanced age-related macular degeneration on the National Eye Institute's Visual Function Questionnaire-25.
Patnaik JL; Lynch AM; Pecen PE; Jasso M; Hanson K; Mathias MT; Palestine AG; Mandava N
Acta Ophthalmol; 2021 Nov; 99(7):750-755. PubMed ID: 33377625
[TBL] [Abstract][Full Text] [Related]
20. Social/economic costs and quality of life in patients with haemophilia in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
